Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H21FN5O4S.C5H14NO |
Molecular Weight | 586.678 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CCO.CCC(=O)[N-]S(=O)(=O)C1=CC(NC2=NC(NC3=CC=C(OCC#C)C=C3)=C(F)C=N2)=CC=C1C
InChI
InChIKey=LZMBOMHVTNXZSS-UHFFFAOYSA-M
InChI=1S/C23H22FN5O4S.C5H14NO/c1-4-12-33-18-10-8-16(9-11-18)26-22-19(24)14-25-23(28-22)27-17-7-6-15(3)20(13-17)34(31,32)29-21(30)5-2;1-6(2,3)4-5-7/h1,6-11,13-14H,5,12H2,2-3H3,(H3,25,26,27,28,29,30);7H,4-5H2,1-3H3/q;+1/p-1
Molecular Formula | C23H22FN5O4S |
Molecular Weight | 483.515 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C5H13NO |
Molecular Weight | 103.1628 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:04:38 GMT 2023
by
admin
on
Sat Dec 16 12:04:38 GMT 2023
|
Record UNII |
02STA794M3
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
121596578
Created by
admin on Sat Dec 16 12:04:38 GMT 2023 , Edited by admin on Sat Dec 16 12:04:38 GMT 2023
|
PRIMARY | |||
|
1620142-65-5
Created by
admin on Sat Dec 16 12:04:38 GMT 2023 , Edited by admin on Sat Dec 16 12:04:38 GMT 2023
|
PRIMARY | |||
|
02STA794M3
Created by
admin on Sat Dec 16 12:04:38 GMT 2023 , Edited by admin on Sat Dec 16 12:04:38 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
But fostamatinib was always the company's primary RA play, and in 2012 Rigel moved R348 also referred to as R-932348 into a phase I study in 36 patients with mild to moderate dry eye. Findings showed the drug was well tolerated, and in May 2013 Rigel decided to move the wholly owned compound into phase II development. Rigel Pharmaceuticals Inc. left open the tiniest prospect for success for dry eye candidate R348 after the Janus kinase/spleen tyrosine kinase (JAK/SYK) inhibitor missed both primary and secondary endpoints in a phase II study.
|